Clinical Trials Sponsored by Shanghai Miracogen Inc.

Total 180 results

Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Advanced or Metastatic Urothelium Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

China
Shanghai Miracogen Inc.

Recruiting

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

China
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

China
Shanghai Miracogen Inc.

Not yet recruiting

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Squamous Cell Carcinoma of the Head and Neck

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Breast Cancer With Liver Metastases

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Locally Advanced Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recurrent or Metastatic Nasopharyngeal Carcinoma

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Advanced or Metastatic Biliary Tract Cancer

China
Shanghai Miracogen Inc.

Completed

A Study of MRG003 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Advanced Malignant Solid Tumors

China
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction Carcinoma

China
Shanghai Miracogen Inc.

Not yet recruiting

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Non-small- Cell Lung Cancer (NSCLC)

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States, China
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Advanced or Metastatic Biliary Tract Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Advanced or Metastatic Breast Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Advanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction Cancer

United States
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

Chronic Lymphocytic Leukemia (CLL) | Cutaneous T-cell Lymphoma (CTCL) | Mycosis Fungoides (MF) | Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype | Adult T-Cell Leukemia/Lymphoma (ATLL)

United States
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers

Healthy Volunteers

Canada
miRagen Therapeutics, Inc.

Terminated

PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study (PRISM)

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

United States, France, Belgium
miRagen Therapeutics, Inc.

Terminated

SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides (SOLAR)

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

United States, France, Spain, Canada, United Kingdom, Australia, Italy, Belgium
miRagen Therapeutics, Inc.

Completed

Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids

Keloid

United States
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers

Healthy Volunteer

United States
Shanghai Genomics, Inc.

Completed

A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis (HBV)

Hepatitis B, Chronic

China
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
Shanghai Kechow Pharma, Inc.

Not yet recruiting

Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

Non-small-cell Lung Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumor | Classic Hodgkin Lymphoma

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

B-cell Non-Hodgkin's Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

IMM40H Phase I Dose Escalation and Expansion

Tumor
Shanghai Kechow Pharma, Inc.

Recruiting

HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

Melanoma

China
Shanghai JMT-Bio Inc.

Completed

Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

Bone Metastases From Solid Tumors

China
Shanghai Kechow Pharma, Inc.

Completed

Study of HL-085 in NRAS Mutant Advanced Melanoma

Melanoma

China
Shanghai Kechow Pharma, Inc.

Completed

HL-085 in NRAS-mutated Advanced Melanoma

Melanoma

China
Shanghai JMT-Bio Inc.

Active, not recruiting

Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone

Giant Cell Tumor of Bone

China
Shanghai Zhimeng Biopharma, Inc.

Completed

A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R

Hepatitis B, Chronic | Healthy Volunteers

China
Shanghai Zhimeng Biopharma, Inc.

Completed

A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants

Healthy Volunteers

United States
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Squamous Cell Non-small Cell Lung Cancer
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai Zhimeng Biopharma, Inc.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B

Chronic Hepatitis b
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Advanced Solid Tumor | Advanced Gastric Carcinoma | Advanced Cholangiocarcinoma | Advanced Lung Cancer

China
Shanghai JMT-Bio Inc.

Recruiting

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Stomach Cancer

China
Shanghai JMT-Bio Inc.

Recruiting

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Oncology | CTLA4 Haploinsufficiency

China
Shanghai Kechow Pharma, Inc.

Recruiting

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

Solid Tumor

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Terminated

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Hematologic Malignancy

China
Shanghai Kechow Pharma, Inc.

Terminated

Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC

Nsclc

China

3

Subscribe